COVID-19 mRNA vaccine immunogenicity decay and breakthrough illness in adolescents and young adults with childhood-onset rheumatic diseases

Yeo, Joo Guan; Teh, Kai Liang; Chia, Wan Ni; Book, Yun Xin; Hoh, Sook Fun; Gao, Xiaocong; Das, Lena; Zhang, Jinyan; Sutamam, Nursyuhadah; Poh, Su Li; Lim, Amanda Jin Mei; Sh, Tay; Yaung, Katherine Nay; Ong, Xin Mei; Leong, J. Y.; Wang, Lin‐Fa; Albani, Salvatore; Arkachaisri, Thaschawee

doi:10.1093/rheumatology/kead031

Cited by 2 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The assay does not employ live virus or cells and can be completed within 1–2 h in a BSL2 laboratory. Previous studies have successfully used cPass to detect SARS-CoV-2 NAbs following a COVID-19 diagnosis 6 or after vaccination of healthcare workers 6 – 8 and other general populations 9 – 11 , as well as adolescents and young adults with childhood-onset rheumatic diseases 12 . The assay’s specificity was demonstrated with samples collected before the emergence of SARS-CoV-2 13 – 15 .…”

Section: Introductionmentioning

confidence: 99%

Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection

Ferrari,

Ruggiero,

Stefani

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Accessible SARS-CoV-2-specific immunoassays may inform clinical management in people with HIV, particularly in case of persisting immunodysfunction. We prospectively studied their application in vaccine recipients with HIV, purposely including participants with a history of advanced HIV infection. Participants received one (n = 250), two (n = 249) or three (n = 42) doses of the BNT162b2 vaccine. Adverse events were documented through questionnaires. Sample collection occurred pre-vaccination and a median of 4 weeks post-second dose and 14 weeks post-third dose. Anti-spike and anti-nucleocapsid antibodies were measured with the Roche Elecsys chemiluminescence immunoassays. Neutralising activity was evaluated using the GenScript cPass surrogate virus neutralisation test, following validation against a Plaque Reduction Neutralization Test. T-cell reactivity was assessed with the Roche SARS-CoV-2 IFNγ release assay. Primary vaccination (2 doses) was well tolerated and elicited measurable anti-spike antibodies in 202/206 (98.0%) participants. Anti-spike titres varied widely, influenced by previous SARS-CoV-2 exposure, ethnicity, intravenous drug use, CD4 counts and HIV viremia as independent predictors. A third vaccine dose significantly boosted anti-spike and neutralising responses, reducing variability. Anti-spike titres > 15 U/mL correlated with neutralising activity in 136/144 paired samples (94.4%). Three participants with detectable anti-S antibodies did not develop cPass neutralising responses post-third dose, yet displayed SARS-CoV-2 specific IFNγ responses. SARS-CoV-2 vaccination is well-tolerated and immunogenic in adults with HIV, with responses improving post-third dose. Anti-spike antibodies serve as a reliable indicator of neutralising activity. Discordances between anti-spike and neutralising responses were accompanied by detectable IFN-γ responses, underlining the complexity of the immune response in this population.

show abstract

Section: Introductionmentioning

confidence: 99%

Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection

Ferrari,

Ruggiero,

Stefani

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The assay does not employ live virus or cells and can be completed within 1-2 hours in a BSL2 laboratory. Previous studies have successfully used cPAss to detect SARS-CoV-2 NAbs following a COVID-19 diagnosis (6) or after vaccination of healthcare workers (6-8) and other general populations (9)(10)(11), as well as adolescents and young adults with childhood-onset rheumatic diseases (12). The assay's speci city was demonstrated with samples collected before the emergence of SARS-CoV-2 (13)(14)(15).…”

Section: Introductionmentioning

confidence: 99%

Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV Infection

Ferrari,

Ruggiero,

Stefani

et al. 2023

Preprint

View full text Add to dashboard Cite

Background. Accessible SARS-CoV-2-specific immunoassays may inform clinical management in people with HIV, particularly in case of persisting immunodysfunction. We prospectively studied their application in vaccine recipients with HIV, purposely including participants with a history of advanced HIV infection. Methods. Participants received one (n=250), two (n=249) or three (n=42) doses of the BNT162b2 vaccine. Adverse events were documented through questionnaires. Sample collection occurred pre-vaccination and a median of 4 weeks post-second dose and 14 weeks post-third dose. Anti-spike and anti-nucleocapsid antibodies were measured with the Roche Elecsys chemiluminescence immunoassays. Neutralising activity was evaluated using the GenScript cPAss surrogate virus neutralisation test, following validation against a Plaque Reduction Neutralization Test. T-cell reactivity was assessed with the Roche SARS-CoV-2 IFNγ release assay. Results. Primary vaccination (2 doses) was well tolerated and elicited measurable anti-spike antibodies in 202/206 (98.0%) participants. Anti-spike titres varied widely, influenced by previous SARS-CoV-2 exposure, ethnicity, intravenous drug use, CD4 counts and HIV viremia as independent predictors. A third vaccine dose significantly boosted anti-spike and neutralising responses, reducing variability. Anti-spike titres >15 U/mL correlated with neutralising activity in 136/144 paired samples (94.4%). Three participants with detectable anti-S antibodies did not develop neutralising responses post-third dose, yet displayed SARS-CoV-2 specific IFNγ responses. Conclusions: SARS-CoV-2 vaccination is well-tolerated and immunogenic in adults with HIV, with responses improving post-third dose. Anti-spike antibodies serve as a reliable indicator of neutralising activity. Discordances between anti-spike and neutralising responses may be accompanied by detectable IFN-γ responses, underlining the complexity of the immune response in this population.

show abstract

COVID-19 mRNA vaccine immunogenicity decay and breakthrough illness in adolescents and young adults with childhood-onset rheumatic diseases

Cited by 2 publications

References 36 publications

Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection

Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection

Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV Infection

Contact Info

Product

Resources

About